HT 4253
Alternative Names: HT-4253Latest Information Update: 14 Oct 2024
Price :
$50 *
At a glance
- Originator Halia Therapeutics
- Class Antidementias; Small molecules
- Mechanism of Action LRRK2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Alzheimer's disease
Most Recent Events
- 01 Sep 2024 Phase-I clinical trials in Alzheimer's disease (In volunteers) in Australia (PO) (NCT06537817)
- 05 Aug 2024 Halia Therapeutics plans a phase I trial for Alzheimer's disease (In volunteers) in Q4 2024 (PO, Tablet) (NCT06537817)
- 19 Dec 2023 Halia Therapeutics plans to file IND application in 2024 (Halia Therapeutics pipeline, December 2023)